Amy Knorr
Neurology · Norwalk, CTNPI 1255432043
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,580 and has fallen 92.1% since, to $125 in 2025.
Across 92 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$263
- Biogen$256
- Amgen$170
- Teva Pharmaceuticals USA, Inc.$131
- Supernus Pharmaceuticals, Inc.$94
- Novartis$86
- plus $849 from 21 others
Across 1 payment — averaging $11,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$11K
What the payments were for
- Speaking & faculty fees$241%
- Food & beverage$1,80397%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 15 | $263 |
| Biogen | 12 | $256 |
| Amgen | 3 | $170 |
| Teva Pharmaceuticals USA, Inc. | 8 | $131 |
| Supernus Pharmaceuticals, Inc. | 5 | $94 |
| Novartis | 4 | $86 |
| EMD Serono, Inc. | 5 | $74 |
| Sanofi | 4 | $71 |
| AstraZeneca | 4 | $66 |
| CSL Behring | 3 | $62 |
| AbbVie(2 entities) | 4 | $60 |
| Adamas Pharmaceuticals, Inc. | 3 | $60 |
| Akcea Therapeutics, Inc. | 2 | $57 |
| Avanir Pharmaceuticals, Inc. | 3 | $47 |
| Neurocrine Biosciences, Inc. | 2 | $42 |
| Eisai Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $35 |
| Amneal Pharmaceuticals LLC | 2 | $34 |
| Boston Scientific | 1 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Acorda Therapeutics, Inc | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Genentech USA, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| MDD US Operations, LLC | 1 | $19 |
| Grifols USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,849 in reported general payments places this provider in the 55th percentile of 280 neurology providers in Connecticut.
Other neurology in Norwalk
- Peter McAllisterFairfield$2.3M
- Stewart TepperStamford$1.2M
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Wanda Castro-BorreroFarmington$553K
- Derek SmithNorwich$469K
- Deena KuruvillaWestport$440K
- Duarte MachadoCheshire$426K
- Tanya BilchikEast Hartford$361K
- Peter GottschalkFairfield$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.